About this trial
Research indicates a strong correlation between cancer and thrombosis, with approximately 20% of blood clots in the U.S. being cancer-related, according to CDC data. Cancer patients face a 4-7 times higher risk of thrombosis compared to non-cancer individuals. Certain cancer treatments, such as chemotherapy and targeted therapy, elevate the likelihood of venous thromboembolism (VTE). Cancer patients with VTE exhibit a significantly higher hazard ratio (H.R.) of 3.4 compared to those without VTE.
This study aims to explore three main topics: (1) Comparing the differences and similarities of leukocyte populations between cancer-associated thrombosis (CAT) and venous thromboembolism (VTE). (2) Characterizing the factors contributing to increased incidence of cancer-associated thrombosis (CAT), with the hypothesis that circulating tumor microemboli (CTM) may express more thrombosis-related proteins than CTCs. (3) Understanding the effects of aspirin or NOACs on cancer-associated thrombosis and CTM formation.
Eligibility criteria
Qualifiers
age≧18
participants (1)participants without cancer: without cancer in five years (2)participants with cancer:pathology reveal have malignant tumor
patients who underwent catheter-based thrombectomy
agree do the thrombectomy
Disqualifiers
participants without cancer (1).shock (2).severe sepsis (3).with cancer in five years
participants with cancer (1).shock (2).severe sepsis
Trial design
Treatments tested in this trial
- CTCs/CTMs culture